Diabetes :: Exubera – Inhaled Insulin Combination for Treatment of Diabetes

There is a new, potential alternative for many of the more than 5 million Americans who take insulin injections, with the Food and Drug Administration’s approval today of the first ever inhaled insulin. Exubera, an inhaled powder form of recombinant human insulin (rDNA) for the treatment of adult patients with type 1 and type 2 diabetes, is the first new insulin delivery option introduced since the discovery of insulin in the 1920s.

Diabetes :: Weight Loss Improves Bladder Control in Women with Prediabetes

Losing a modest amount of weight through dietary changes and increased physical activity reduces the occurrence of urinary incontinence (UI) in women with prediabetes, a condition in which blood glucose levels are higher than normal but not yet diabetic. This finding comes from a new study, published in the February issue of Diabetes Care, of women who participated in the Diabetes Prevention Program (DPP), a landmark clinical study funded by the National Institutes of Health (NIH).

Cancer :: Sutent, sunitinib for Gastrointestinal – Stomach Cancer, Kidney Cancer

The Food and Drug Administration (FDA) announced approval of Sutent (sunitinib), a new targeted anti-cancer treatment for patients with gastrointestinal stromal tumors (GIST), a rare stomach cancer, and advanced kidney cancer. This action marks the first time the agency has approved a new oncology product for two indications simultaneously.

SIDS :: SIDS increases in the cold winter

The number of infants who die from Sudden Infant Death Syndrome, or SIDS, increases in the cold winter months, according to the National Institute of Child Health and Human Development (NICHD), one of the National Institutes of Health. During these colder months, parents often place extra blankets or clothes on infants, hoping to provide them with more warmth. In fact, the extra material may actually increase infants’ risk for SIDS.